Ultomiris FDA Approval Gives Soliris Biosimilars Bigger Hurdle
New Rapid Infusion Formulation Bolsters Originator
Alexion Pharmaceuticals’ Soliris (eculizumab) blockbuster represents a significant opportunity for biosimilar sponsors around the globe. Ahead of anticipated US competition in 2025, the originator has added a new formulation for next-generation product Ultomiris (ravulizumab-cwvz).
